Purpose: We determined if and to what extent longitudinal changes in lower urinary tract symptoms are related to disease specific and generic quality of life in men.
Due to population aging and the availability of new, minimally invasive treatments increasing attention is being given to the impact of lower urinary tract symptoms (LUTS) on quality of life (QOL). In LUTS symptom severity has been reported to have a significant impact on physical and social functioning, mental health, and the perception of health and general well-being. 1Ϫ7 The severity of LUTS, measured as the frequency of symptoms rated by the patient, and bother, as experienced by the patient, are important determinants for intervention. Since the presence of symptoms does not necessarily reflect the experience of them, the concept of QOL as a consequence of LUTS is of interest.
Data on the relationship between LUTS severity and QOL is largely based on cross-sectional studies. 2Ϫ6 Because LUTS likely is to be associated with other morbidity, it follows that the relationship between LUTS and QOL may be confounded by such comorbidity. This methodological problem can in part be overcome by measuring the relationship between the change with time in LUTS and in QOL. However, few studies have examined the relationship between long-term changes in LUTS severity and changes in QOL scores with time. 1, 8, 9 Therefore, in this longitudinal study we determined if and to what extent changes in LUTS are related to changes in QOL.
MATERIALS AND METHODS
The Krimpen Study is an ongoing, longitudinal, community based population study of 50 to 75-year-old men, in which the natural history of LUTS and its relationship to general wellbeing was surveyed. After baseline evaluation 2 followup rounds were completed. The design of the Krimpen Study has been extensively described previously. 10 Briefly, all 3,924 eligible men 50 to 75 years old in Krimpen aan den IJssel were invited to participate, of whom 50% responded. All men provided written informed consent. The Medical Ethics Committee of Erasmus Medical Centre Rotterdam approved the study.
Participants completed a questionnaire, including the short version of the Inventory of Subjective Health (Mini-ISH), 3 domains of the Sickness Impact Profile (SIP), the International Prostate Symptom Score (I-PSS) and the benign prostatic hyperplasia Impact Index (BII). Moreover, they underwent various physical and urological measurements. Based on the results of digital rectal examination and prostate specific antigen prostate biopsies were done to exclude prostate cancer.
If no prostate cancer was detected, participants had not moved outside of the municipality, they were alive and no exclusion criteria were met, a re-invitation letter was mailed to all participants for followup. Two consecutive rounds of followup were performed with an average followup of 2.1 and 4.2 years, respectively. In these rounds all measurements were repeated.
QOL questionnaires. Generic measurements are commonly used to measure changes in QOL due to a disease or treatment in terms that are applicable to every individual irre- spective of a specific diagnosis. These questionnaires enable the comparison of QOL data on different groups of patients. In this study we used Mini-ISH and SIP as generic QOL questionnaires. Mini-ISH is a 13 item questionnaire on subjective health with a score range of 0 to 13. 11 The 3 SIP domains used in this study were emotions, feelings and sensations (emotions, including 9 items), leisure pastimes and recreation (recreation, 8 items) and social interaction (social, 20 items). For each category a score was calculated based on weighing factors for each item, providing scores of from 0 to 100. 12 In contrast to generic QOL questionnaires, disease specific questionnaires measure QOL based on items closely related to the specific disease and, therefore, they are expected to be more sensitive. To measure the effect of LUTS on QOL we used the QOL question of I-PSS (I-PSS-QOL) and BII. I-PSS-QOL can be rated on a scale of 0 to 6. 13 The BII is a 4 question index with a score of 0 to 13 that is designed to assess the impact of benign prostatic hyperplasia symptoms on health status. 5 For all scales used (disease specific and generic) a higher score indicates worse QOL.
LUTS. LUTS were categorized according to I-PSS as mild-0 to 7, moderate-8 to 19 or severe-20 to 35. 13 We defined clinical LUTS as moderate to severe symptoms (I-PSS greater than 7).
A few groups have investigated which change in I-PSS leads to an observable change in QOL. 14, 15 For example, in patients with clinically progressive LUTS Barry et al reported that a worsening in I-PSS of at least 3.1 points was needed for the patient to perceive the change. 15 On the other hand, in the Medical Therapy of Prostatic Symptoms a worsening of total I-PSS of at least 4 points according to an arbitrary demarcation (based on a 3 point improvement in symptom scores when receiving ␣-blockers) was used to determine the number of patients with clinical progression of LUTS.
14 In the current study based on the distribution over the participant subgroups we defined changes in I-PSS as clear worsening-4 points or greater, slight worsening-less than a 4 points increase, no change, slight improvementless than a 4 points decrease and clear improvement-a 4 point or greater decrease.
Analysis. Analysis focused on mean I-PSS and QOL scores at baseline and at the second followup (mean followup of 4.2 years). To determine if baseline LUTS severity was a determinant of nonresponse at the second study followup we compared mean I-PSS at baseline in participants with and without data available at the second followup. Statistical comparisons between the groups were performed using the paired t test with statistical significance considered at the 0.05 level.
Pearson's correlations between all QOL measurements at baseline, and between all QOL measurements at baseline and I-PSS at baseline were used to determine the sensitivity of QOL measures used. QOL changes with time in relation to LUTS were analyzed in different subgroups depending on baseline I-PSS and the change in I-PSS with time. Multiple linear regressions analysis was used to test the relationships between changes in QOL, changes in I-PSS, different baseline-I-PSS levels and age. Table 1 lists characteristics of the study population according to age and I-PSS. At the second followup 882 men (80.3%) participated, of whom 19 had no I-PSS data available during baseline measurement. In men without data at the second followup mean baseline I-PSS was 6.2 compared with 5.2 in men with available data. Of the men with complete data during the followup of 4.2 years 178 showed clear worsening of LUTS, 88 showed clear improvement, and 597 showed slight or no changes in LUTS. Table 1 also shows QOL scores at baseline and at 4.2 years of followup. Mean generic QOL scores improved significantly with time in all men as well as in men with significant LUTS. There was no significant change in disease specific values (I-PSS-QOL and BII) in all men. However, in men with significant LUTS these 2 scores decreased significantly. An increase in I-PSS-QOL with age was observed at baseline and at followup. Table 2 shows the annual change in I-PSS and I-PSS-QOL in European men (Krimpen Study) compared with these changes in men in North America (Olmsted County) and Asia (Japan). 8, 9 In all studies the average annual I-PSS change generally increased with age. However, in the Krimpen Study and the Olmsted County study there was little or no average change in I-PSS-QOL with time, which was fairly consistent across age groups. Japanese results showed a diffuse pattern over the age groups.
RESULTS
QOL instruments were tested for mutual correlation (table  3) . Generic QOL measures and the 2 disease specific QOL measures showed significant correlation, providing evidence for the sensitivity of the generic instruments. The correlation between the generic QOL instruments and baseline I-PSS was low but statistically significant.
Overall 28.6% of the men reported a clear or slight improvement in LUTS after 4.2 years. The mean change in I-PSS in the clear worsening subgroup was 6.6 in men with mild symptoms at baseline and 6.3 in those with moderate to severe symptoms at baseline. In men in the clear improve- 
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ment subgroup the mean change in I-PSS was Ϫ4.6 in those with mild symptoms at baseline and Ϫ7.5 in those with moderate to severe symptoms at baseline. Table 4 shows changes in QOL related to changes in LUTS. With time generic QOL scores decreased, indicating better QOL, independent of baseline I-PSS and the I-PSS change between baseline and the second followup. Table 4 also shows that in QOL disease specific measures there was significant improvement and significant worsening depending on the subgroup. It should be noted that, although in some subgroups I-PSS-QOL worsened, the average score of this measurement nevertheless indicated general satisfaction with the condition. 13 Men in the clear worsening, slight worsening, slight improvement and improvement subgroups showed no intergroup differences regarding age, smoking/drinking behavior, marital status, the number of children or level of education.
Changes in QOL with time were analyzed for each QOL score separately. Table 5 shows changes in generic and disease specific QOL measures according to an increase of 4 points on I-PSS. Linear regression models, which included I-PSS at baseline, change in I-PSS between baseline and followup, and age, showed that 0.8% of the change in Mini-ISH could be predicted by the model (explained variance 0.8%, p ϭ 0.069). For SIP Social, SIP emotional and SIP recreation the explained variance was 1.4% (p ϭ 0.006), 0.7% (p ϭ 0.112) and 1.1% (p ϭ 0.023), respectively. This low explained variance indicates that better reported QOL measured by the generic instruments could not be attributable to changes in LUTS (table 3) . Using the same explanatory variables for the disease specific QOL changes 14.7% of the I-PSS-QOL change could be predicted by this model (r 2 p Ͻ0.0001), as could 16.5% of the variance in BII (r 2 p Ͻ0.0001).
DISCUSSION
The results of our longitudinal study show that changes in the severity of LUTS, defined as changes in symptom frequency as measured by I-PSS, have little impact on disease specific QOL and hardly any impact on generic QOL in men who are 50 to 79 years old. Considering the suggested progressiveness of LUTS with time the only slight increase in mean I-PSS in our study population during 4.2 years is remarkable. Selective loss of respondents is not an adequate explanation for this small increase. Men who quit the study after baseline measurement or at 2.1 years of followup also showed only a modest increase in I-PSS with time.
The longitudinal annual change in the Olmsted County study also increased with age, although this annual change was higher than in our participants. 8 In contrast to these and our results, mean scores in men in the Japanese study decreased. 9 Differences in followup and the number of data points (shorter followup and fewer data points in the Japanese study) could be an explanation for these differences.
The overall health status of our participants as measured by generic QOL questionnaires improved during followup. Participants in our study had SIP scores comparable to those in an unselected Dutch population but better QOL as measured by SIP than patients with nonspecific abdominal symptoms. 16 Only the mean score on the recreation domain of the SIP of our participants was higher than the score of the 2 reference groups, which could be explained by the higher age of our participants.
In the current study disease specific QOL of men deteriorated with increasing I-PSS. However, most men seem to have had few problems with LUTS because the average score on I-PSS-QOL in the different subgroups indicates "in gen- .36* Mean change was calculated by subtracting baseline from followup data with negative mean change indicating improved QOL and statistical analysis between baseline and followup performed using paired t test (I-PSS groups based on baseline I-PSS-mild vs moderate to severe and I-PSS change with time of less than 4, or 4 or greater points). * Significant at p ϭ 0.05. eral satisfied." Thus, despite the significant changes measured in I-PSS-QOL we emphasize that this does not necessarily imply clinically relevant changes.
The positive change in generic QOL in this study could not be attributed to baseline LUTS severity or a change in LUTS with time. Although QOL instruments were found to be sensitive and in a large part of the population we saw I-PSS changes of 4 or more points, we must realize that the change in I-PSS causes only a small change in disease specific QOL. This change may be too small to cause a measurable effect on generic questionnaires.
Normally one would expect reported QOL to decrease with aging. However, in the current study we found the opposite result. Better generic QOL might be explained by participants reaching retirement age during the study period, more spare time, less work related stress and other kinds of daily activities. This discrepancy between the increase in LUTS and worse disease specific QOL on one hand and better generic QOL on the other hand might also be explained by coping strategies. Studies have shown that coping behavior, that is the way that one manages stressful situations and circumstances, affects psychological, physical and social wellbeing. 17, 18 Because LUTS was not the topic of investigation in those latter studies, to our knowledge the relationship between coping behavior and changes in perceived QOL in men with a change in LUTS severity remains to be explored.
The results of our longitudinal study in the community show that there is interaction between LUTS and QOL but it is not as large as expected. Obviously there are other populations or subgroups with more extreme changes in LUTS severity that may show larger effects on QOL.
From our cross-sectional analyses we earlier concluded that LUTS is strongly related to suboptimal well-being. 6 Also based on cross-sectional data, others concluded that men with moderate and severe LUTS identified in a large American cohort had poor health status in several important QOL dimensions. 3, 6 Bertaccini et al also suggested that LUTS largely influences perceived QOL in men. 19 Thus earlier conclusions about the relationship between LUTS and QOL in cross-sectional data, including the Krimpen Study, seemed justified. However, after analyzing the longitudinal data of the Krimpen Study the relationship between LUTS and QOL must be reconsidered. The differences between results based on cross-sectional and on longitudinal data are mainly attributable to study design differences but they may also be due to comorbidity, which occurs more frequently in patients with LUTS and is known to have a negative effect on QOL. Because we have previously observed an association between LUTS, erectile dysfunction and QOL, we suggest that in men with LUTS and poor QOL the general practitioner or urologist should also assess for curable comorbidity that could adversely affect QOL. 6 Longitudinally our data show that there is a slight average increase in disease specific QOL with time. This is in line with data from North America and Asia. 8, 9 No attention was given to the impact of potential treatments in this population because our analyses were specifically targeted to changes. LUTS and QOL separately can be affected by treatment but it is not probable that treatment has an impact on the relationship between LUTS and QOL. The influence of treatment for LUTS in relation to changes in QOL is a topic of future research in the Krimpen Study.
CONCLUSIONS
From our population based study we conclude that a change in LUTS during a followup of 4.2 years had only a small impact on disease specific QOL and hardly any impact on generic QOL in men who were 50 to 79 years old. These results imply that men with LUTS do not perceive a considerable influence of these symptoms on general well-being. In turn this could suggest the need for more restraint in the intervention policy in men with LUTS.
